Q3 2025 13F Holders as of 9/30/2025
-
Type / Class
-
Equity / Common Stock, $0.0001 par value per share
-
Shares outstanding
-
31.5M
-
Number of holders
-
165
-
Total 13F shares, excl. options
-
32.5M
-
Shares change
-
+6.51M
-
Total reported value, excl. options
-
$3.11B
-
Value change
-
+$680M
-
Put/Call ratio
-
1.43
-
Number of buys
-
119
-
Number of sells
-
-41
-
Price
-
$95.76
Significant Holders of Cidara Therapeutics, Inc. - Common Stock, $0.0001 par value per share (CDTX) as of Q3 2025
196 filings reported holding CDTX - Cidara Therapeutics, Inc. - Common Stock, $0.0001 par value per share as of Q3 2025.
Cidara Therapeutics, Inc. - Common Stock, $0.0001 par value per share (CDTX) has 165 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 32.5M shares
.
Largest 10 shareholders include RA CAPITAL MANAGEMENT, L.P. (3.37M shares), Bain Capital Life Sciences Investors, LLC (3.02M shares), Point72 Asset Management, L.P. (1.58M shares), BVF INC/IL (1.41M shares), Vivo Capital, LLC (1.31M shares), VANGUARD GROUP INC (1.23M shares), BlackRock, Inc. (1.17M shares), Darwin Global Management, Ltd. (997K shares), Paradigm Biocapital Advisors LP (961K shares), and VR ADVISER, LLC (947K shares).
This table shows the top 165 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.